Monoclonal Discovery
Find your ideal therapeutic antibody with Alloy Discovery Services
A fully integrated, precision approach to creating the ideal antibodies to meet your therapeutic goals.
Qualified leads in as fast as 4 months
Creating antibodies with therapeutic potential requires a precision approach to generating, retrieving, and assessing antibodies with the specific properties required for the intended therapeutic effect.
Start broader
Campaigns begin by leveraging our best-in-class in vivo discovery platforms with 6 mouse strains to produce the broadest possible diversity of high quality, fully human antibody sequences against your target of interest.
Screen smarter
Based on your program’s specific affinity, specificity, and developability criteria, we’ll utilize one of our proprietary workflows for B cell enrichment followed by deep sequencing and AI/ML powered in silico repertoire mining to interrogate and identify the best hits.
Sprint forward
We convert hits to therapeutic candidates by deploying our full-stack analytical capabilities to characterize affinity, specificity, epitope binning, cell binding, drug-like properties, and in vitro and in vivo functional testing.
Discover the ideal antibodies for therapeutic intent to accelerate your path to the clinic with confidence
End-to-end expertise
Every step managed from antigen qc to final candidate selection.
Advanced technology
For antibody generation, screening, selection, and analysis.
PRoven delivery
Trusted by biopharma, startups, and academics for delivering on desired targets.
An expert team deploying an optimized workflow to accelerate antibody discovery
We offer a tailored approach to get you qualified leads by leveraging proprietary methodologies to find and develop antibodies that meet your targets profile
Driving optimal outcomes by maximizing initial diversity of high quality leads
We design each discovery campaign to maximize sequence and epitopic diversity by leveraging Alloy’s suite of transgenic mice for fully human antibody discovery combined with a range of immunization methods tailored to your target.
- ATX-GK strain for human kappa light chain antibodies
- ATX-GL strain for lambda antibodies
- ATX-GKH hyperimmune strain for challenging targets such as GPCRs
- ATX-CLC common light chain strain for bispecific generation
For each campaign, we design an optimal immunization strategy based on target biology and criteria for affinity and specificity. We have extensive experience immunizing ATX mice with diverse antigens including recombinant proteins, LNP encapsulated mRNA and DNA, and cell lines. All antigens are fully QC’d prior to immunization to ensure successful outcomes.
Immunization methods
- Soluble protein & peptide
- Cell-based
- Proprietary adjuvants
- Genetic (DNA & RNA)
- RIMMS protocols
- Proprietary protocols to break tolerance
Advanced wet lab and in silico tools to select the most promising candidates
- B cells are harvested from multiple tissues and binders enriched through our proprietary MACS, FACS, or immune library based approaches followed by deep sequencing to capture the full antibody diversity.
- AI/ML in silico tools are applied to a select panel of hundreds of antibody candidates that maximize diversity across clones and clonotypes while filtering for sequences predicted to have poor developability.
- Using our proprietary mAbForge™ workflows, predicted binders are produced and characterized for affinity, specificity, and cell binding within 3 weeks. Additional diversity from the sequenced repertoire can be mined if needed to optimize properties, enabling rapid identification of hits with desired characteristics.
Recovery and selection
- NGS sequencing informatics
- B cell enrichment
- Scalable, high-throughput analysis
- Antibody repertoire analysis
- Immune libraries
- In silico clone selection
Advancing with confidence through comprehensive antibody characterization
- Affinity
- Specificity
- Cross-reactivity
- Epitope binning
- Drug-like properties
This robust package offers everything you and we need to make informed, data driven decisions at the earliest stages of discovery to select high quality, manufacturable leads for successful therapeutic development. We can also provide additional functional testing where needed.
Candidate assessment
- Antibody production
- Flexible expression formats
- Cross reactivity and specificity
- Epitope binning
- Developability package
- Cell binding validation
Additional services to accelerate your drug candidate towards the clinic
AI/ML-driven engineering & optimization
Bispecific engineering
Combine monoclonal leads into panels of bispecific candidates by leveraging our common light chain (ATX-CLC) platform or various diverse light chain formats. Rapidly identify bispecific leads with desired functional attributes and drug-like properties with our fully integrated workflows.
Translational medicine
Preclinical services including in vitro and in vivo functional testing to provide the comprehensive data to select your functional leads. Our translational medicine team has extensive experience with a diverse array of assays including ADCC, ADCP, T-cell killing, cytokine release, cellular internalization, and functional reporter assays.
Antibody humanization
Starting with a non-human antibody or VHH from another source? We deploy our in silico and high-throughput production platforms to rapidly humanize binders from a variety of species. We can also parallel track humanization of existing binders with de novo discovery of fully human clones to ensure that you end up with the best antibody for your program.
In vitro
AI-enabled
In vivo
Start your next monoclonal discovery campaign with us
Lets create your ideal therapeutic antibody together. We’ll craft a tailored discovery approach for optimal outcomes designed to meet your therapeutic objectives.
Moncolonal news & resources
